Parameter description | Base case value |
---|---|
Model structure | Two state Markov cohort model |
Modelled cycle length | 1 month |
Time horizon | Lifetime |
Costs and effects discount rate per annum | 3.50% |
Parametric survival model CV mortality | Gompertz |
Extrapolation CV mortality post trial | Gompertz |
Regression model hospitalisation | Poisson |
Regression model NYHA class | Generalised ordered logistic |
Regression model QoL | Multilevel model |
Drug costs per month (£) | |
Standard care average cost per month | 9.54 |
Ivabradine average cost per month | 42.10 |
Other therapy related costs (£) | |
ECG unit cost | 31.28 (12.01–44.30) |
CV specialist visit unit cost | 118.81 (89.48–138.97) |
Hospitalisations cost per event ( £) | |
HF diagnosis (general ward) | 2307.98 |
HF diagnosis (cardiac ward) | 3295.12 |
Other CV diagnosis (general ward) | 1942.44 |
Other CV diagnosis (cardiac ward) | 1729.60 |
Non-CV diagnosis (general ward) | 2643.56 |
Admission type given hospitalisation | |
Proportion of hospitalised patients admitted in cardiac specialist ward versus general ward | 50% (40–60%) |
Other resource use | |
Ongoing HF management costs per month | 26.77 |
Regression equations reported in online supplementary technical appendix.
Ivabradine average dose=6.7794 mg, British National Formulary list price £40.17 per pack.
HF hospitalisation weighted average of HRG (Health Resource Group) codes: EB03H–EB03I.
Cardiovascular hospitalisation weighted average HRG codes: EA03Z–EB10Z.
All-cause hospitalisation HRG weighted average codes AA02Z–WA23Y.
CV, cardiovascular; HF, heart failure; NYHA, New York Heart Association; QoL, quality of life.